WO2007076055A3 - Compositions and methods comprising proteinase activated receptor antagonists - Google Patents

Compositions and methods comprising proteinase activated receptor antagonists Download PDF

Info

Publication number
WO2007076055A3
WO2007076055A3 PCT/US2006/049117 US2006049117W WO2007076055A3 WO 2007076055 A3 WO2007076055 A3 WO 2007076055A3 US 2006049117 W US2006049117 W US 2006049117W WO 2007076055 A3 WO2007076055 A3 WO 2007076055A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
activated receptor
proteinase activated
receptor antagonists
Prior art date
Application number
PCT/US2006/049117
Other languages
French (fr)
Other versions
WO2007076055A2 (en
WO2007076055A9 (en
Inventor
Todd A Hembrough
Gregory E Agoston
Anthony M Treston
Arthur D Hanson
Original Assignee
Entremed Inc
Todd A Hembrough
Gregory E Agoston
Anthony M Treston
Arthur D Hanson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc, Todd A Hembrough, Gregory E Agoston, Anthony M Treston, Arthur D Hanson filed Critical Entremed Inc
Publication of WO2007076055A2 publication Critical patent/WO2007076055A2/en
Publication of WO2007076055A9 publication Critical patent/WO2007076055A9/en
Publication of WO2007076055A3 publication Critical patent/WO2007076055A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

Compositions and methods comprising proteinase activated receptor antagonists are provided. More particularly, the present invention relates to the use of proteins, peptides and molecules that bind to proteinase activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.
PCT/US2006/049117 2005-12-22 2006-12-21 Compositions and methods comprising proteinase activated receptor antagonists WO2007076055A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75336305P 2005-12-22 2005-12-22
US60/753,363 2005-12-22

Publications (3)

Publication Number Publication Date
WO2007076055A2 WO2007076055A2 (en) 2007-07-05
WO2007076055A9 WO2007076055A9 (en) 2007-08-30
WO2007076055A3 true WO2007076055A3 (en) 2008-02-28

Family

ID=38218681

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049117 WO2007076055A2 (en) 2005-12-22 2006-12-21 Compositions and methods comprising proteinase activated receptor antagonists

Country Status (1)

Country Link
WO (1) WO2007076055A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005368A2 (en) * 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
RU2009127095A (en) 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) NEW OXADIAZOLE COMPOUNDS
ES2395583T3 (en) * 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A) PIRIDINES and compounds related to activity against CB2 cannabinoid receptors
WO2009038842A2 (en) * 2007-06-15 2009-03-26 Mission Pharmacal Co. Methods and compositions to inhibit edema factor and adenylyl cyclase
ATE554078T1 (en) 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc SYNTHESIS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 INHIBITORS
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
JP5769970B2 (en) 2007-11-16 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Aryl- and heteroarylcarbonyl derivatives of benzomorphan and related skeletons, medicaments containing such compounds and their use
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2722427A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200950780A (en) 2008-05-13 2009-12-16 Boehringer Ingelheim Int Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
CN102112445B (en) * 2008-06-09 2014-06-18 百时美施贵宝公司 Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110050459A (en) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
JP2012505836A (en) 2008-10-17 2012-03-08 アカール ファーマ ピーティーワイ リミテッド S1P receptor modulators and their use
TW201022266A (en) * 2008-10-23 2010-06-16 Boehringer Ingelheim Int Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010057101A2 (en) * 2008-11-17 2010-05-20 Schering Corporation Compounds useful as hiv blockers
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
MA33216B1 (en) 2009-04-30 2012-04-02 Boehringer Ingelheim Int CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5656986B2 (en) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1 based on 1,3-oxazinan-2-one structure
FR2947452B1 (en) * 2009-07-01 2012-04-20 Fabre Pierre Dermo Cosmetique L-SERINE AND / OR L-ASPARAGINE AND / OR L-VALINE FOR PREVENTING AND / OR TREATING INFLAMMATORY SKIN REACTIONS.
TWI531571B (en) 2009-11-06 2016-05-01 維它藥物公司 Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
KR101478889B1 (en) 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 Pyrazolopyrimidine compounds and their use as pde10 inhibitors
WO2011137089A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
JP5860042B2 (en) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Substituted 5, 6 and 7 membered heterocycles, medicaments containing such compounds and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
CN103140488A (en) * 2010-08-03 2013-06-05 加利福尼亚大学董事会 Compounds and compositions for mitigating tissue damage and lethality
EP2616450B1 (en) 2010-09-17 2018-05-02 Kancera AB Sulfonamide compounds
AU2011325286B2 (en) 2010-11-02 2015-04-16 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CN108484589A (en) 2010-11-05 2018-09-04 赛诺米克斯公司 The useful compound of conditioning agent as TRPM8
TWI537258B (en) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
CN103347860A (en) * 2010-11-15 2013-10-09 Abbvie公司 Nampt inhibitor
TW201238950A (en) 2010-11-15 2012-10-01 Abbott Lab NAMPT and rock inhibitors
FR2970965A1 (en) * 2011-01-31 2012-08-03 Centre Nat Rech Scient ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF
KR101298651B1 (en) * 2011-03-16 2013-08-21 연세대학교 산학협력단 Pharmaceutical Compositions for Enhanced Anti-angiogenic Activities
WO2013025664A1 (en) 2011-08-17 2013-02-21 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
US8633198B1 (en) 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
US9708276B2 (en) 2011-10-12 2017-07-18 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
SG11201401818RA (en) 2011-10-26 2014-05-29 Allergan Inc Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2014013751A (en) * 2012-05-11 2015-08-07 Abbvie Inc Pyridazine and pyridine derivatives as nampt inhibitors.
CA2912048A1 (en) * 2012-05-15 2013-11-21 Calasia Pharmaceuticals, Inc. Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90
AU2013288265B2 (en) 2012-07-09 2017-04-06 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
US9951055B2 (en) * 2012-10-19 2018-04-24 Massachusetts Institute Of Technology Thiazole-based inhibitors of scavenger receptor BI
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
US9850264B2 (en) * 2013-03-06 2017-12-26 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
US9771327B2 (en) 2013-03-13 2017-09-26 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
US20160046616A1 (en) * 2013-03-15 2016-02-18 The Johns Hopkins University Nrf2 small molecule inhibitors for cancer therapy
CN103232406B (en) * 2013-04-26 2015-07-29 北京大学 A kind of 1,3-thiazoles derivative
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
CA2924690A1 (en) 2013-09-25 2015-04-02 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
TWI657085B (en) 2013-10-04 2019-04-21 英菲尼提製藥股份有限公司 Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015088516A1 (en) * 2013-12-11 2015-06-18 Nant Holdings Ip, Llc Small molecule inhibitors of influenza a rna-dependent rna polymerase
WO2015110999A1 (en) * 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
JP6324777B2 (en) * 2014-03-18 2018-05-16 ポーラ化成工業株式会社 Collagen production promoter
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
CN107205970A (en) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 Immunomodulator
UY36390A (en) * 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US10618899B2 (en) 2015-02-18 2020-04-14 Buck Institute For Research On Aging Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau
JP6746614B2 (en) * 2015-05-27 2020-08-26 杏林製薬株式会社 Urea derivative or its pharmacologically acceptable salt
KR20180058741A (en) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 Solid form of isoquinolines, a process for their preparation, compositions comprising them and methods for using them
CA2999503A1 (en) * 2015-09-23 2017-03-30 Minerva Biotechnologies Corporation Method of screening for agents for differentiating stem cells
JP6865743B2 (en) 2015-10-01 2021-04-28 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as activity regulators of TRPM8
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN107663159A (en) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 Polycyclic compound, its pharmaceutical composition and application
US11084807B2 (en) 2016-08-18 2021-08-10 Vidac Pharama Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
WO2018081167A1 (en) * 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
US20200246285A1 (en) * 2017-08-03 2020-08-06 Georgetown University Small molecule inhibitors of slc25a1
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN107915671A (en) * 2017-11-30 2018-04-17 兰州大学 The derivative and preparation method and purposes of a kind of Fascaplysin
CN112074511A (en) * 2018-03-01 2020-12-11 托马斯·黑勒戴药物研究基金会 Substituted benzodiazoles and their use in therapy
CN110314161A (en) * 2018-03-30 2019-10-11 潍坊医学院 Purposes of the compound in the drug of preparation treatment tumour
KR20210015833A (en) * 2018-05-04 2021-02-10 레미디 플랜, 인크. Cancer treatment targeting cancer stem cells
BR112020022406A2 (en) * 2018-05-09 2021-04-13 Glucox Biotech Ab COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND, METHOD FOR THE TREATMENT OF A DISORDER
GB201809050D0 (en) * 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
US20220112157A1 (en) * 2018-09-05 2022-04-14 The University Of British Columbia Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
CN109293537A (en) * 2018-11-12 2019-02-01 中国药科大学 Sulfamide compound and its medical usage
WO2020223590A1 (en) * 2019-05-02 2020-11-05 Constellation Pharmaceuticals, Inc. Modulators of trex1
CN113527327A (en) * 2021-07-29 2021-10-22 守恒(厦门)医疗科技有限公司 Thienopyrrole amide derivatives and application thereof in antitumor drugs
EP4163273A1 (en) 2021-10-07 2023-04-12 Universita' Degli Studi Di Pavia Substituted vinyl piperazine-piperidine urea derivatives as anticancer agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266687A1 (en) * 2002-06-26 2004-12-30 Todd Hembrough Compositions and methods comprising protein activated receptor antagonists
US20050026946A1 (en) * 2003-06-27 2005-02-03 Pfizer Inc GSK-3 inhibitors
WO2005030773A1 (en) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. Novel pyrazolopyrimidine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266687A1 (en) * 2002-06-26 2004-12-30 Todd Hembrough Compositions and methods comprising protein activated receptor antagonists
US20050026946A1 (en) * 2003-06-27 2005-02-03 Pfizer Inc GSK-3 inhibitors
WO2005030773A1 (en) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. Novel pyrazolopyrimidine derivatives

Also Published As

Publication number Publication date
WO2007076055A2 (en) 2007-07-05
WO2007076055A9 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007076055A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2006023844A3 (en) Compositions and methods comprising proteinase activated receptor antagonists
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2007022225A3 (en) Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
TW200740844A (en) Novel MAdCAM antibodies
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
EP2772260A3 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2006102557A3 (en) Treatment of protein degradation disorders
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007061874A3 (en) Methods and compositions for use in treating cancer
UA102867C2 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2006008028A8 (en) Novel 6-formyltetrahydropteridines method for production and use thereof as medicament against cancer amongst other things
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2007022121A3 (en) O-nitro compounds, pharmaceutical compositons thereof and uses thereof
WO2006122123A3 (en) Methods of alleviating disorders and their associated pain
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848966

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)